George Simeon | CEO
Curevo Vaccine

George Simeon, CEO, Curevo Vaccine

George Simeon is the CEO of Curevo Vaccine. He joined Curevo at the beginning of 2019 and has over 30 years of experience in the healthcare sector working with multinational firms, start-ups, and not-for-profits. He has worked in biotech, pharmaceuticals, medical devices, IVD, and healthcare convergence technologies. He has worked extensively in Europe, Asia, and North America. Before moving to the USA, he was based in South Korea from 2014-2018, where he worked for SK Telecom’s Healthcare Division in M&A and global strategic alliances. In 2016, he joined Sollers Partners, a cross-border investment advisory firm, while maintaining an advisory role with SK Telecom. He has worked across Europe and the USA as an executive with Johnson & Johnson, as the founding Vice-President of Cordis Neurovascular Europe, and with GHX Europe as a Commercial Vice-President. He also spent 3 years with Novartis Global Headquarters in Switzerland working on projects in their CNS portfolio in Health Economics and Pricing. George has also founded two start-ups and advised GS1 on their global entry and expansion into the Healthcare, High-Tech, and Customs sectors as well as on ESG practices in FMCG logistics. George is a graduate of INSEAD (MBA) and Yale University (MPH).

Appearances:



Day 3 - Thursday 31st October @ 13:30

Tolerability and Immunogenicity of Amezosvatein, a New Recombinant Herpes Zoster Vaccine with a Novel Adjuvant

Session led by: curevo-vaccine
last published: 11/Oct/24 16:15 GMT

back to speakers